Primary Recommendation

Dechra Pharmaceuticals - New animal drug could be blockbuster

October 2004

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Over the month we met with Ian Page, chief executive of Dechra Pharmaceuticals, which manufactures and sells pharmaceutical products mainly to the animal health market. Dechra is best known as the largest wholesaler of such products to the UK's veterinary profession, a business which has recovered well after a wobble early last year and recent forecast busting results paint a very positive outlook for the future. However, much of the recent re-rating in the shares comes from interest in its proprietary pharmaceutical portfolio with investors holding high hopes for Vetoryl, Dechra's new treatment for Cushing's disease in dogs, which is being hailed as a potential blockbuster. Vetoryl is already selling like hot ca ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

NETeller - Online payment processor has makings of a multi-bagger

NCC Group - Escrow solutions group makes strong debut

Dechra Pharmaceuticals (November 2010)

Dechra Pharmaceuticals - US launch of Vetoryl to boost profits (February 2010)

Dechra Pharmaceuticals (November 2008)

Dechra Pharmaceuticals - US blockbuster potential for key drug (August 2008)

Dechra Pharmaceuticals - Impending US drug approval could herald profit surge (April 2007)

Dechra Pharmaceuticals - Gains approach Â£1 per share (November 2005)

Dechra Pharmaceuticals (April 2005)

Dechra Pharmaceuticals - Positive AGM (December 2004)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X